BiotechTube

Roxadustat + Epoetin Alfa

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia in Incident Dialysis Patients

Conditions

Anemia in Incident Dialysis Patients

Trial Timeline

Feb 11, 2014 → Sep 21, 2018

NCT ID
NCT02052310

About Roxadustat + Epoetin Alfa

Roxadustat + Epoetin Alfa is a phase 3 stage product being developed by Astellas Pharma for Anemia in Incident Dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02052310. Target conditions include Anemia in Incident Dialysis Patients.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT02052310Phase 3Completed
NCT01147666Phase 2Completed

Competing Products

20 competing products in Anemia in Incident Dialysis Patients

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
84
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85